Menopause and Restless Legs Syndrome: What the Evidence Actually Shows

Menopause and restless legs syndrome overlap, but falling estrogen has not been shown to cause RLS, and HRT is not a proven RLS treatment. The checks that change the plan are the five-part symptom pattern, a full iron panel, medication timing, untreated sleep apnea, and look-alikes that need a different response.

The iron point is the one that changes appointments. A result your laboratory calls “normal” can still sit inside an RLS treatment-consideration range—and two current expert documents do not draw the upper line in the same place. We will show you both without pretending the disagreement is settled.

---

Is this page for you?

Best for you if: you get a strong urge to move one or both legs when you sit or lie still, moving helps while you keep moving, the feeling is worse in the evening or at night, and it is costing you sleep.

Not for you if: your main symptom is crawling or prickling on the skin without the urge–rest–movement–night pattern. That points toward a different workup—start with menopause and formication. A sudden hard, painful muscle contraction is more consistent with a cramp. These problems can coexist, so the full pattern matters more than any single word you use for the sensation.

Get medical care promptly if: one leg develops new swelling, pain or tenderness, warmth, or red or discolored skin—especially when more than one of those signs appears together. The CDC lists those as common signs of deep vein thrombosis, or DVT. Call 911 or go to an emergency department now for leg symptoms with chest pain, trouble breathing, a fast or irregular heartbeat, fainting or lightheadedness, or coughing up blood. Also call 911 for sudden face or arm weakness, trouble speaking, new vision trouble, or sudden loss of balance. None of that is ordinary restless legs. (CDC: blood clots; CDC: stroke signs)

A sensation in one leg, by itself, is not proof of a clot. New swelling, tenderness, warmth, discoloration, breathing symptoms, or sudden neurologic symptoms are what change the plan.

---

The short version

Your question	The bottom line
Does menopause cause restless legs?	Not proven. The strongest menopause-specific association is with hot flashes and night sweats, not menopausal status itself.
Will HRT fix it?	Current evidence does not support HRT as an RLS treatment. The only randomized estrogen trial measured nighttime limb movements—not diagnosed RLS—and found no benefit.
What is the most actionable check?	Iron status. The 2025 AASM guideline calls for ferritin and transferrin saturation and uses RLS-specific treatment-consideration thresholds that can sit above a laboratory’s general lower reference limit.
What may be aggravating it?	Alcohol, caffeine, sedating antihistamines, serotonergic medicines, dopamine-blocking medicines, and untreated obstructive sleep apnea are all named in current guidance.
What is first-line now?	Confirm the pattern, address aggravators, assess iron, then discuss treatment. The AASM strongly recommends gabapentin enacarbil, gabapentin, and pregabalin and conditionally recommends against standard long-term use of several dopamine agonists because of augmentation.
Does magnesium work?	The evidence remains inconclusive. A 2019 review found only eight usable studies; a later add-on trial does not establish that magnesium works by itself.

---

Who wrote this, and how

The HRT Index is the independent decision resource for online menopause and HRT care — comparing telehealth providers on clinical legitimacy, care quality, medication fit, price transparency, and access, with every claim verified and dated, so women can choose the path that fits their situation before their first consult.

We are not clinicians, and this page has not been reviewed by one. We read the primary documents and recorded what they actually say—including where current expert documents disagree. For this page, that meant the International Restless Legs Syndrome Study Group diagnostic criteria, the 2025 American Academy of Sleep Medicine treatment guideline, the updated 2026 Mayo Clinic Proceedings algorithm from the Restless Legs Syndrome Foundation’s scientific and medical advisory board, the 2018 iron consensus report, FDA drug labels, The Menopause Society’s 2023 nonhormone statement, the menopause–RLS studies, and the magnesium evidence.

You will find the full source ledger near the bottom. Where the evidence cannot answer a question, we say so instead of filling the gap with a mechanism that merely sounds convincing.

One thing we want to say plainly before you go further: if you raised this with a clinician and were told it was “just menopause,” you were not wrong to keep looking. RLS is diagnosed from a five-part pattern, and the first workup should also look for iron status, aggravating medicines, untreated sleep apnea, and conditions that mimic RLS.

Before we go on

The right online HRT provider isn't the same for every woman — it depends on your symptoms, your age and whether you have a uterus, your medication route preference (patch, pill, gel, or vaginal estrogen), your risk history, your insurance or cash-pay situation, and your state. Some situations belong with an in-person clinician first. Because a general answer can't resolve those for you, use The HRT Index's Find My HRT Path tool to match your situation to the right provider — and to flag when online care isn't the right starting point — before your first consult.

For leg symptoms that may be RLS, the first stop is usually primary care, sleep medicine, or neurology—not an online HRT provider. That is especially true when the five-part pattern is incomplete, you have never had a full iron panel, another neurologic or sleep condition may be involved, or any warning sign is present. Menopause care belongs in the plan when hot flashes, night sweats, bleeding changes, or the separate HRT decision also need attention.

---

What is the connection between menopause and restless legs syndrome?

The short answer: RLS is more common in women and becomes more common with age, and some women first notice it during the menopause transition. But the strongest menopause-specific studies link RLS or periodic limb movements with vasomotor symptoms—hot flashes and night sweats—rather than menopausal status itself. No study has proved that falling estrogen directly causes RLS.

That answer is not a dodge. It changes what you do next. A direct estrogen cause would point toward hormone replacement as the central fix. The evidence instead points toward a symptom-pattern check, iron studies, medication review, sleep evaluation, and a separate decision about treating hot flashes or night sweats.

We identified four studies that directly examined menopause, estrogen, RLS, or nighttime periodic limb movements and compared them side by side. They do not all measure the same outcome, which is exactly why the distinction matters.

The menopause–restless legs evidence ledger

Study	What it was	What it measured	What it found
Wesström et al., 2008 (PubMed)	Questionnaire sent to a random sample of 5,000 Swedish women aged 18–64; 70.3% responded	Self-reported RLS, menopause status, HRT use, hot flashes, and night sweats	15.7% reported RLS. RLS was strongly associated with vasomotor symptoms. The study found no statistical relationship with being postmenopausal or using HRT.
Wesström et al., 2014 (PubMed)	348 women underwent overnight polysomnography	Objectively scored periodic limb movements during sleep	Clinically significant limb movements were associated with hot flashes and night sweats after adjustment. Menopausal status, assessed with FSH, was not associated.
Polo-Kantola et al., 2001 (PubMed)	Double-masked, placebo-controlled crossover trial; 71 women enrolled and 62 completed	Incidence and intensity of nocturnal periodic limb movements during estrogen and placebo periods	Estrogen at doses used for climacteric symptoms did not change the incidence or intensity of nighttime limb movements.
Hachul et al., 2007 (PubMed)	One-patient case report	Periodic limb movements before and after an estradiol patch	Improvement was reported in that one patient. A case report can generate a question; it cannot outweigh a randomized trial.

The part nobody mentions

Look at the last two rows again.

The 2001 paper was a randomized, placebo-controlled crossover trial with objective nighttime movement measurement. It found no effect. The 2007 paper was one patient, yet its title reads like a general finding: “Estrogen therapy reduces nocturnal periodic limb movements.”

That mismatch is how a topic becomes more certain online than it is in the evidence. One positive case report is easier to repeat than a null trial with an inconvenient distinction in the outcome.

That distinction cuts both ways: periodic limb movements are not the same thing as RLS. Periodic limb movements are objective movements counted during sleep. RLS is a clinical diagnosis based on what you feel while awake. They frequently overlap, but no randomized trial has tested estrogen in women selected for diagnosed RLS. The honest conclusion is: the randomized evidence we have points to no effect on nighttime limb movements, while a direct estrogen trial in diagnosed RLS has not been done.

Why “low estrogen causes restless legs” is too simple

Age and menopause happen at the same time. RLS becomes more common with age in both women and men. A study that simply finds more RLS after menopause has not separated hormones from age. That is why the 2014 sleep-study result matters: the vasomotor-symptom association remained, while menopausal status itself did not.

A plausible pathway is not a demonstrated cause. Estrogen interacts with dopamine biology, and dopamine pathways are involved in RLS. That makes the question biologically plausible. It does not show that declining estrogen causes RLS in women or that replacing estrogen treats it.

Hormone levels are not part of the diagnosis. There is no estrogen, FSH, or other hormone result that confirms or rules out RLS. A hormone panel cannot replace the clinical pattern or the evaluation for contributing conditions.

None of that means you imagined the timing. It means “Is it my hormones?” is not the question most likely to get your legs—and your sleep—unstuck.

---

How do I know if this is really restless legs syndrome?

The short answer: RLS is diagnosed by a five-part pattern, and all five parts matter: an urge to move the legs, onset or worsening during rest, relief with movement, evening or nighttime predominance, and no simpler condition that explains the symptoms better. There is no blood test, scan, or sleep study that proves a classic case.

The criteria come from the International Restless Legs Syndrome Study Group’s 2014 consensus update. (IRLSSG criteria)

#	Ask yourself	Why it matters
1	Do I get an urge to move one or both legs, usually with an uncomfortable or hard-to-describe feeling?	The urge is central. Pain, tingling, or twitching without an urge to move is not enough.
2	Does it start or get worse when I am sitting or lying still?	RLS is tied to rest or inactivity.
3	Does movement make it better—at least while I keep moving?	Relief with walking, stretching, or movement is characteristic.
4	Is it worse in the evening or at night than earlier in the day?	Circadian timing is part of the diagnostic pattern.
5	Is there a better explanation, such as a cramp, positional discomfort, swelling, neuropathy, arthritis, medication-induced restlessness, or a habitual movement?	The 2014 update formalized this fifth criterion to keep mimics from being mislabeled as RLS.

The most useful sensory clue

The 2014 criteria paper’s historical discussion describes RLS sensations as being felt “deep down inside the legs” rather than on the skin. That is a useful discriminator, not an absolute exclusion rule. The stronger signal is the complete urge–rest–movement–night pattern.

Crawling strictly on the skin without an urge to move points somewhere else. Deep internal discomfort plus an urge to move that appears at rest and eases with movement fits RLS more closely.

What “movement helps” really means

Relief is often partial and temporary. You stand up, it eases, you return to bed, and it comes back. That cycle is not proof that you are failing to “relax.” It is part of the pattern clinicians ask about.

RLS can involve the arms, especially when symptoms are severe, long-standing, or augmented by dopaminergic treatment. But every nighttime twitch is not RLS, and that fifth criterion exists because mimics are common.

Restless legs versus kicking during sleep

A partner saying you kick all night is useful information, but it is not an RLS diagnosis. Periodic limb movements are observed during sleep. RLS is an awake sensation and urge that usually appears before sleep or during quiet rest. They can occur together; neither term should be substituted for the other.

The words people reach for

People describe electricity in the calves, fizzing deep in the legs, a pressure that only movement interrupts, or the brutal combination of being exhausted and unable to stay still. Those words can help you recognize the experience. They do not identify the cause by themselves.

Not sure whether you meet all five? Use the printable seven-night pattern record below. It captures the criteria, timing, movement response, medication changes, bleeding history, and sleep loss on one page—without pretending to diagnose you. Jump to the appointment record →

---

Could this be leg cramps, neuropathy, medication restlessness, or a clot instead?

The short answer: Several conditions can feel “restless” without meeting the RLS pattern. A hard focal cramp, persistent numbness or weakness, whole-body inner restlessness after a medicine change, kicking only during sleep, or new one-sided swelling points toward a different lane—and some of those lanes are urgent.

This is a routing table, not a diagnostic tool. More than one condition can be present at the same time.

What you notice	Fits classic RLS?	Consider instead	Where to start	How fast
Urge to move, starts or worsens at rest, eases with movement, worse at night, no better explanation	Yes—classic pattern	Iron status, medicine effects, untreated sleep apnea, kidney or nerve conditions, family history	Primary care or sleep medicine; ask about iron studies and a medication review	Routine unless sleep loss is severe or safety is affected
Sudden painful tightening; one muscle becomes hard	Less typical	Nocturnal leg cramp	Primary care if frequent, severe, or new	Faster with swelling, injury, or weakness
Burning, persistent numbness, reduced sensation, weakness, or balance trouble; movement does not reliably help	Less typical	Peripheral neuropathy, radiculopathy, or another neurologic problem	Primary care, then neurology if indicated by the exam	Prompt for new weakness or progressive symptoms
Whole-body inner restlessness, pacing, inability to sit still after a medication start or dose change	May be akathisia	Medication effect, often involving dopamine-blocking medicines	Contact the prescriber or pharmacist; do not stop an essential medicine on your own	Prompt if severe or escalating
Partner sees repeated kicking, but you have no awake urge to move	Not enough for RLS	Periodic limb movements, sleep apnea, or another sleep disorder	Sleep medicine if sleep or daytime function is affected	Routine unless breathing pauses or dangerous sleepiness are present
You wake hot, sweating, or with a racing heart but have no urge–rest–movement pattern	Probably a separate lane	Vasomotor symptoms, insomnia, panic, or another cause of awakening	Menopause care or primary care	Routine unless chest symptoms or other warning signs are present
Heavy or changing perimenopausal bleeding plus fatigue or a history of low iron	Could contribute through iron loss	Abnormal uterine bleeding and iron depletion	Gynecology or primary care plus iron studies	Bleeding changes deserve evaluation; any bleeding after menopause needs prompt assessment
Symptoms began after a new antidepressant, allergy or sleep product, or anti-nausea medicine	Possible aggravating factor	Medicine-associated worsening	Prescriber or pharmacist review; bring exact products and dates	Do not stop abruptly
One leg develops new swelling, pain or tenderness, warmth, or red/discolored skin	Not a wait-and-see RLS pattern	DVT	Medical evaluation	Promptly; follow local emergency guidance
Leg symptoms plus chest pain, trouble breathing, fainting, fast or irregular heartbeat, or coughing blood	No	Pulmonary embolism	Emergency services	Immediately
Sudden face or arm weakness, speech trouble, vision change, severe imbalance, or sudden severe headache	No	Stroke	Emergency services	Call 911 now

---

Why can a “normal” iron result still matter for restless legs?

The short answer: RLS guidance uses treatment-consideration thresholds that are different from a laboratory’s general reference range. The 2025 AASM guideline says adults with clinically significant RLS should have ferritin and transferrin saturation checked and considers iron treatment when ferritin is 75 ng/mL or below or transferrin saturation is under 20%.

If you take one thing from this page, take this section.

The question women keep asking is: My iron was normal. Could it still matter?

Yes. A general “normal” flag does not answer an RLS-specific iron question. These thresholds are not a diagnosis of iron deficiency, and they are not permission to self-treat. They are clinician-facing decision points that sit inside a full panel, symptoms, medical history, and assessment for the cause of any low result.

The numbers that change the conversation

Result or range	What current guidance says	What it does not mean
Ferritin ≤75 ng/mL or transferrin saturation <20%	The 2025 AASM good-practice statement says oral or intravenous iron may be considered in adults with clinically significant RLS. (AASM guideline)	It does not mean every person should start iron without testing, contraindication review, or a plan to find the cause.
Ferritin 75–100 ng/mL	The AASM statement places this in an IV-iron-only consideration range because oral absorption is expected to be limited.	It does not mean IV iron is automatic or appropriate for every symptom pattern.
Ferritin 75–300 ng/mL with transferrin saturation <45%	The 2026 Mayo Clinic Proceedings algorithm extends IV-iron consideration into this range for selected patients with persistent clinically significant RLS when the broader clinical conditions fit. (2026 algorithm)	A ferritin of 150 does not, by itself, make someone an IV-iron candidate. The symptom diagnosis, transferrin saturation, prior oral iron response or suitability, urgency, and individual risks still matter.
Transferrin saturation at or above 45%	This falls outside the broader 2026 algorithm’s stated transferrin-saturation condition and changes the iron-overload conversation.	It is not a number to work around with over-the-counter iron. It needs clinician interpretation.

The AASM explicitly labels its ferritin and transferrin-saturation cutoffs as consensus thresholds “which have not been empirically tested.” That is the guideline telling you the lines are expert judgment, not a universal biological switch.

A full iron panel is more than a CBC

The useful RLS iron assessment includes ferritin, serum iron, total iron-binding capacity, and transferrin saturation. The AASM advises drawing the panel in the morning and avoiding iron-containing supplements and foods for at least 24 hours beforehand. Follow the preparation instructions on your own laboratory order.

A complete blood count does not measure iron stores. You can have a normal hemoglobin and still have a ferritin or transferrin-saturation result that changes an RLS discussion.

The AASM–Mayo split

This is the most decision-relevant disagreement on the page.

The 2025 AASM guideline uses ferritin 75–100 ng/mL as its IV-only consensus band. The 2026 Mayo algorithm reaches as high as 300 ng/mL for selected patients when transferrin saturation remains below 45% and the rest of the clinical picture supports IV iron.

That does not mean one document says “no” and the other says “yes” to every woman with a ferritin between 100 and 300. It means the newer algorithm permits a broader specialist discussion than the AASM good-practice statement. If your result lands in that gap, ask which guidance your clinician is using and why.

The ferritin-assay problem underneath the thresholds

A 2025 study tested the same 116 clinical samples with two commercial ferritin assays. The methods tracked closely, but the absolute values differed. (Silber, Block, and St. Louis, 2025)

Beckman result	Approximate Roche-equivalent result
50	83
75	121
100	158
300	457

The authors could not determine which assays had been used in the foundational studies behind current cutoffs. Their practical conclusion was not to ignore the numbers. It was to interpret ferritin flexibly and use transferrin saturation too.

That is worth one sentence at your appointment: “Which ferritin assay did this lab use, and are you interpreting the result with transferrin saturation rather than ferritin alone?”

Why this can matter more in midlife women

In a clinical RLS sample, 53.7% of women versus 22.2% of men had ferritin below 75 ng/mL. That does not prove iron caused every woman’s symptoms, but it shows why an RLS-specific iron check is not a throwaway step. (Holzknecht et al.)

Perimenopause adds an obvious iron-loss pathway: heavier or less predictable bleeding can deplete iron before anemia appears. If your bleeding has changed, that is not a side conversation. It belongs in the same appointment—and the bleeding itself needs evaluation rather than being written off as “just perimenopause.” See HRT for perimenopausal heavy periods.

Do not start iron before the test

We know how tempting it is. Three reasons to get the baseline first:

Supplements can obscure the starting point. Once you begin iron, later testing no longer shows the untreated baseline as cleanly.

Iron is not harmless. Excess iron can accumulate, and a high transferrin-saturation result changes the plan. The point of testing is to identify who may benefit and who may be harmed.

A low result has a cause. Heavy bleeding, gastrointestinal blood loss, diet, absorption problems, pregnancy, kidney disease, and other conditions do not become less important because an iron bottle raised the number.

What to say at the appointment

“My symptoms follow the rest–movement–night pattern. Would a full iron panel be appropriate—ferritin, serum iron, total iron-binding capacity, and transferrin saturation—and how would you interpret those results specifically for RLS? I understand the treatment-consideration thresholds differ from general laboratory reference ranges.”

Take the numbers with you. The printable appointment record includes both current threshold frameworks, space for your own results, and the exact medication and bleeding timeline that changes the interpretation. Jump to the printable record →

---

Which medicines and everyday habits can make restless legs worse?

The short answer: Current AASM guidance says the first step is to address aggravating factors—including alcohol, caffeine, antihistaminergic medicines, serotonergic medicines, dopamine-blocking medicines, and untreated obstructive sleep apnea. For a woman treating hot flashes, nausea, allergies, or insomnia, several can be sitting in plain sight.

This is where menopause care and RLS can collide. We put The Menopause Society’s 2023 hot-flash recommendations beside the 2025 AASM guideline, the 2026 RLS algorithm, and current FDA approvals. The overlap is more useful than another generic “avoid triggers” list.

The cross-guideline matrix

Option	For hot flashes or night sweats	In current RLS guidance	What that means in practice
SSRIs and SNRIs	Recommended, Level I, by The Menopause Society in 2023	Serotonergic medicines are named as aggravating factors. The 2026 algorithm says most antidepressants may worsen RLS, with bupropion as a noted exception.	A real timing question for the prescriber—not permission to stop. Bupropion is not recommended by the AASM as an RLS treatment.
Low-dose paroxetine (Brisdelle)	FDA-approved for moderate-to-severe vasomotor symptoms; also an SSRI	Falls inside the serotonergic-medicine watch category	The fact that it is FDA-approved for hot flashes does not tell you what it will do to your RLS pattern. Sudden discontinuation is not the answer.
Gabapentin	Recommended, Level I, by The Menopause Society	Strongly recommended by the AASM for RLS; off-label for RLS in the United States	The one medicine explicitly recommended in both the 2023 menopause statement and 2025 RLS guideline. That makes it a reasonable discussion when both problems are present—not an automatic prescription.
Pregabalin	Not recommended for vasomotor symptoms, Level III, in the 2023 statement	Strongly recommended by the AASM for RLS; off-label for RLS in the United States	Strong RLS evidence does not make it a preferred hot-flash treatment.
Fezolinetant (Veozah)	FDA-approved for moderate-to-severe vasomotor symptoms; recommended, Level I, in the 2023 statement	Not addressed as an RLS treatment in current guidance	Its RLS effect is unknown. The current FDA label includes liver-testing requirements; that is a separate safety discussion. (FDA)
Elinzanetant (Lynkuet)	FDA-approved in October 2025 for moderate-to-severe vasomotor symptoms; it postdates the 2023 Menopause Society statement	Not addressed as an RLS treatment in current guidance	The draft claim that paroxetine was the only FDA-approved nonhormonal option is no longer true. Elinzanetant’s RLS effect has not been established. (FDA label)
Oxybutynin	Recommended, Levels I–II, in the 2023 statement	Not named as an RLS treatment	No current RLS recommendation is not the same as proof of benefit or harm.
Clonidine	Not recommended for vasomotor symptoms in the 2023 statement	Not a standard current RLS treatment	Weak fit for this particular two-symptom problem.
Menopausal hormone therapy	Remains the most effective treatment for bothersome vasomotor symptoms for appropriate candidates	Not included as an RLS treatment; the randomized estrogen limb-movement trial was null	It may treat the hot flashes that are breaking your sleep. That is different from treating RLS.
Sedating over-the-counter “PM” products	Not menopause treatment, but commonly used when menopause disrupts sleep	Sedating antihistamines are aggravators to review and avoid where clinically possible	Check the active ingredient for diphenhydramine or doxylamine before assuming “sleep aid” means better sleep for RLS.
Some anti-nausea or vertigo medicines	Used for symptoms that can overlap with menopause	Dopamine-blocking medicines and sedating antihistamines are aggravator categories	Metoclopramide and prochlorperazine are dopamine-blocking examples; promethazine and meclizine are sedating antihistamines. Ask a pharmacist about the exact product.

Source: The Menopause Society 2023 position statement, AASM 2025 guideline, FDA menopause information, and the 2026 RLS algorithm.

How to use this table without making a bad decision tonight

You are looking for a timing relationship, and you are taking it to a prescriber or pharmacist. You are not looking for permission to stop a prescription.

Write down the exact medicine, dose, start date, dose-change date, time of day you take it, when the leg symptoms changed, and what benefit the medicine gives you. That last field matters. It turns “Which drug do I blame?” into “What trade-off are we actually solving?”

The hot-flash fork

There are now three FDA-approved nonhormonal therapies for menopausal vasomotor symptoms: low-dose paroxetine, fezolinetant, and elinzanetant. The 2023 Menopause Society statement predates elinzanetant, so a 2026 comparison cannot call paroxetine the only approved nonhormonal option. (FDA overview)

Among the options explicitly evaluated in both the 2023 menopause statement and the 2025 AASM RLS guideline, gabapentin is the overlap: Level I recommended for hot flashes and strongly recommended for RLS. That does not make it right for everyone. It gives you a more precise question than “What can I take for sleep?”

“I have both hot flashes and a symptom pattern that may be RLS. Which treatment addresses both, which might aggravate one of them, and what side effects matter in my situation?”

The sleep aid in your cabinet

Diphenhydramine and doxylamine are sedating antihistamines. They appear in many products with “PM,” “nighttime,” or “sleep” in the name, plus some cold and allergy formulas. Drowsiness is not the same as treating RLS.

If your legs worsened after you began taking something nightly for sleep, turn the box over and read the active ingredient. A pharmacist can tell you whether that exact product falls into an aggravating category and what safer questions to take to your prescriber.

Non-sedating allergy medicines are generally handled differently, but check the exact ingredient instead of relying on the front of the package.

Alcohol, caffeine, and sleep apnea

Alcohol and caffeine are named as aggravators, not universal causes. Change one variable at a time and record what happens. If you overhaul everything at once, you learn nothing about what actually mattered.

Untreated obstructive sleep apnea is also named in the AASM’s first-step aggravator review. If you snore, wake gasping, have witnessed breathing pauses, wake with headaches, or are dangerously sleepy during the day, open that second lane. See how hot flashes, insomnia, and sleep apnea can overlap during menopause.

Your medication timeline

Use one line per product:

Medicine or product → start date or dose-change date → when the legs started or worsened → time of day taken → what happens on missed days → benefit the product gives you

Do not omit supplements, cannabis products, cold medicines, allergy products, sleep aids, or anti-nausea medicines. “Over the counter” does not mean irrelevant.

---

Does HRT help restless legs syndrome?

The short answer: Menopausal hormone therapy is not an established RLS treatment, and current RLS guidance does not include it. HRT may substantially improve hot flashes and night sweats that are fragmenting your sleep, but sleeping better after those symptoms improve is not the same as treating the RLS pattern.

The honest admission

We should say this clearly because it is the thing most likely to cost us your click, and we would rather you trusted the rest of the page.

RLS is not an FDA-approved use for a menopause hormone product. The only randomized estrogen trial measured nighttime limb movements and found no benefit. The strongest menopause-specific association is with hot flashes and night sweats—not menopausal status itself. If you came here hoping we would tell you estradiol fixes RLS, we cannot.

But that is useful news.

It means the next steps are not a blind hormone experiment. The most actionable questions can be checked separately:

1. Does the symptom meet all five RLS criteria?
2. What do ferritin and transferrin saturation show?
3. Did a prescription, supplement, “PM” product, alcohol pattern, or caffeine pattern change first?
4. Is untreated sleep apnea or an RLS mimic in the picture?

Current evidence does not show that estrogen corrects those contributors. HRT can still be the right treatment for hot flashes, night sweats, genitourinary symptoms, or bone-loss prevention in an appropriate candidate. That is a separate decision with its own benefits, risks, route choices, and need for a prescription.

Order of operations beats hope here. Check the RLS pattern and contributors. Then decide about HRT for the symptoms it actually treats.

What hormone therapy is actually for

FDA-approved menopausal hormone therapies are used for indications such as moderate-to-severe vasomotor symptoms, vulvar and vaginal symptoms, and prevention of postmenopausal osteoporosis, depending on the product and route. Systemic treatment and local vaginal treatment solve different problems. Whether HRT fits depends on symptoms, age and timing, whether you have a uterus, medical history, route, dose, and the exact product label. (FDA menopause information)

One boundary matters on this site: FDA-approved hormone products and compounded hormone preparations are not interchangeable categories. Compounded drugs are not FDA-approved, and the FDA does not review their safety, effectiveness, or quality before marketing. Compounding can serve a legitimate patient-specific need when an approved product is not medically appropriate, but nothing on this page suggests a compounded product treats RLS or is equivalent to an FDA-approved product. (FDA: compounded-drug risks)

What if the symptoms changed after I started or changed HRT?

Write down the exact product, route, dose, start date, and dose-change date. Then record everything else that changed in the same window: sleep, bleeding, stress, other prescriptions, supplements, illness, travel, caffeine, alcohol, and over-the-counter sleep products.

No trial has established that HRT worsens RLS. Individual timing still deserves review. Take the timeline to the prescriber rather than stopping hormone therapy on your own.

New one-sided swelling, warmth, tenderness, or discoloration is not something to file under “restless legs” or assume is a routine HRT effect. Get it assessed on its own merits.

If the leg problem is separate but the menopause symptoms are not

Find My HRT Path does not diagnose RLS or interpret an iron panel. It helps you sort the separate menopause-care decision: whether online care is a sensible starting point, which provider model fits your state and insurance, and when an in-person clinician belongs first. Find my menopause-care starting point → About 90 seconds. No email required. The current tool states that answers stay on the page. How we handle consumer health data

---

Does magnesium help restless legs in menopause?

The short answer: Magnesium is not proven to treat RLS. A 2019 systematic review found only eight usable studies—one randomized placebo-controlled trial, three case series, and four single-patient reports—and the randomized trial found no significant benefit. A later 2022 add-on trial was positive at two months but does not establish magnesium as a stand-alone treatment.

Here are the numbers behind the phrase “mixed evidence.”

The 2019 review screened 855 abstracts. Sixteen could not be excluded from the abstracts alone, seven full-text papers could not be located, and eight studies were left with usable data: one randomized trial, three case series, and four case reports. The randomized trial found no significant treatment effect and may have been underpowered. The reviewers concluded that they could not determine whether magnesium was effective. (Marshall et al., 2019)

A later single-blind randomized trial assigned 75 people to magnesium oxide, vitamin B6, or placebo while participants were also receiving pramipexole. It found no group difference at one month and reported differences at two months. Because magnesium was tested as an add-on, the trial cannot tell you what magnesium does by itself. (Jadidi et al., 2022)

Why the stories are still convincing

RLS naturally waxes and wanes. Cramps, neuropathy, formication, and RLS are also commonly confused. Start a supplement during a brutal week and improve during the next one, and the supplement gets the credit whether it caused the change or not.

Your improvement can be real without proving a general treatment effect.

Where we land: magnesium may have another reason to be in your plan, including a documented deficiency. It should not replace the five-part pattern check, medication review, sleep-apnea screen, or full iron panel. Kidney disease, drug interactions, and a growing supplement list are reasons to ask before adding more.

And the warning that costs people the most: do not start iron just because you read a ferritin threshold online. Get the baseline first.

---

How is restless legs syndrome treated in 2026?

The short answer: Treatment starts by confirming RLS, correcting aggravating factors, and assessing iron. For medication, the 2025 AASM guideline strongly recommends gabapentin enacarbil, gabapentin, and pregabalin and conditionally recommends against standard use of pramipexole, ropinirole, and rotigotine because long-term dopaminergic treatment can cause augmentation.

This is a real direction change, and much of the consumer content online still reads as though dopamine agonists are the automatic first choice.

FDA approval and current guideline preference are different questions

Treatment	FDA status for RLS in the United States	What the 2025 AASM guideline says
Ropinirole	FDA-approved for moderate-to-severe primary RLS	Conditionally recommends against standard use, chiefly because of augmentation risk (FDA label)
Pramipexole	FDA-approved for moderate-to-severe primary RLS	Conditionally recommends against standard use (FDA label)
Rotigotine patch	FDA-approved for moderate-to-severe primary RLS	Conditionally recommends against standard use (FDA label)
Gabapentin enacarbil (Horizant)	FDA-approved for moderate-to-severe primary RLS in adults	Strongly recommends (FDA label)
Gabapentin	Not specifically FDA-approved for RLS; prescribed off-label	Strongly recommends
Pregabalin	Not specifically FDA-approved for RLS; prescribed off-label	Strongly recommends
IV ferric carboxymaltose	Not specifically FDA-approved for RLS	Strongly recommends when iron status is appropriate

Among the four medicines in this table with specific FDA RLS indications, three are dopamine agonists that the current guideline conditionally recommends against for standard use. Two of the three strongly recommended gabapentinoids are off-label for RLS.

That is not a contradiction. FDA approval asks whether a product has adequate evidence for a labeled indication. A clinical guideline asks how available options should be used relative to one another in current practice, including long-term harms.

What augmentation means

Augmentation is treatment-induced worsening: symptoms start earlier in the day, begin faster when you sit down, become more intense, last longer, or spread to body areas that were not involved before.

A 52-week randomized trial provides a concrete comparison. Augmentation occurred in 2.1% of participants receiving pregabalin, 7.7% receiving pramipexole 0.5 mg, and 5.3% receiving pramipexole 0.25 mg. The pregabalin difference was statistically significant against the 0.5-mg dose, not the 0.25-mg dose. (Allen et al., 2014)

That single year does not describe every patient’s lifetime risk. It does show why the guideline no longer treats augmentation as a side note.

Do not abruptly stop a dopamine agonist because you recognize the pattern. Withdrawal and symptom rebound need prescriber management. If symptoms now start earlier, are more intense, or have spread, use the word augmentation when you contact the clinician who prescribed it.

The honest downsides of the gabapentinoid-first approach

The first-line shift does not make gabapentinoids harmless.

• The 2026 RLS algorithm reports clinically significant weight gain in roughly 20% of people taking gabapentinoids.
• Dizziness, sleepiness, gait instability, and falls matter more with age, other sedating medicines, alcohol, kidney impairment, and sleep apnea.
• Mood changes deserve attention, especially with a history of severe depression or suicidal thoughts.
• The 2026 algorithm discusses mixed retrospective database signals involving later dementia diagnoses. Those studies do not establish causation, but the uncertainty belongs in an eyes-open medication discussion.
• Misuse risk and combined respiratory depression matter when opioids or other sedatives are involved.

None of that makes a gabapentinoid the wrong choice. It makes “first-line” the beginning of the discussion, not the end.

The steps in order

1. Confirm the pattern. All five criteria, with mimics considered.
2. Address aggravators. Alcohol, caffeine, relevant medicines, and untreated sleep apnea.
3. Assess iron. Ferritin, serum iron, total iron-binding capacity, and transferrin saturation under the preparation instructions on your order.
4. Treat iron when appropriate. Oral or IV treatment depends on the results, symptoms, prior response, absorption, urgency, and risk—not the supplement aisle.
5. Discuss medication if symptoms persist. Ask why a particular class fits, what side effects matter to you, and how augmentation will be monitored.

Current guidance also covers selected refractory cases, including carefully supervised low-dose opioids and bilateral high-frequency peroneal nerve stimulation. Those are specialist discussions, not a menu to self-select from.

---

What can I do about restless legs tonight?

The short answer: Getting up and moving, gentle stretching, massage, and a warm bath or warm or cool pack can give temporary relief. These measures do not identify the cause, and they do not replace evaluation when symptoms are frequent or severe—but you still need to get through tonight.

A low-risk sequence, offered as options rather than a protocol:

1. Get out of bed. Staying still works against the defining pattern.
2. Walk for a few minutes. The goal is relief, not a workout.
3. Stretch gently. Stop if it hurts.
4. Try massage, a warm bath, or a warm or cool pack. Use the option that feels best; no good evidence establishes one as superior.
5. Return to bed when the urge settles. Do not stay there fighting it while frustration climbs.
6. Record the start time, what relieved it, and how long relief lasted. That turns a brutal night into usable information.

What not to do: do not start high-dose iron from an online threshold. Do not stop a prescribed medicine because it appeared in a table. Do not reach nightly for a sedating “PM” product without checking the active ingredient. Do not treat new swelling, warmth, discoloration, chest pain, breathlessness, or sudden neurologic symptoms as routine RLS.

When tonight becomes an appointment: symptoms several nights a week, worsening intensity, severe sleep loss, unsafe daytime sleepiness, symptoms after a medication change, persistent numbness or weakness, or any warning sign.

---

Which doctor should I see for restless legs during menopause?

The short answer: Primary care is the right starting point for many women because it can apply the criteria, examine you, order iron studies, review medicines, evaluate bleeding, and coordinate referral. Sleep medicine or neurology becomes more useful when the diagnosis is unclear, symptoms are severe, augmentation is suspected, or another sleep or nerve disorder may be involved.

Start here	When it fits
Primary care	Classic RLS pattern, no prior full iron panel, medication review needed, other medical conditions in the mix, or referral coordination needed
Sleep medicine	Symptoms still wreck sleep after the first steps; snoring, gasping, witnessed breathing pauses, dangerous daytime sleepiness, or another sleep disorder is suspected
Neurology	Persistent weakness, numbness, balance change, unclear diagnosis, complex treatment, refractory symptoms, or suspected augmentation
Gynecology or menopause care	Heavy or changing bleeding, any bleeding after menopause, or a separate decision about HRT for hot flashes and night sweats
Urgent or emergency care	DVT, pulmonary embolism, stroke, or other warning signs described at the top of this page

A classic RLS presentation usually does not require a sleep study. Testing becomes useful when a separate sleep question—often obstructive sleep apnea or unexplained periodic limb movements—needs answering. It is fair to ask: “What question will the sleep study answer?”

Where can I book a virtual starting point?

A video visit can be useful for history, medication review, and ordering or discussing labs when the clinician decides they are appropriate. It cannot perform a hands-on neurologic exam, diagnose every mimic, or complete a sleep study.

The table below separates provider-stated facts from what those facts mean for this page. Verified August 5, 2026.

Service	Provider-stated facts we verified	When it may fit here	Where it stops
Midi Health	Virtual menopause and midlife care in all 50 states; self-pay $250 initial visit and $150 continued-care visit; in-network with most PPO plans, but coverage varies; not covered by Medicare; Medicare beneficiaries may self-pay but cannot submit related claims; cannot treat Medicaid or Medi-Cal patients even as self-pay; clinicians may order bloodwork or imaging when needed. (Pricing; How Midi works)	You have a separate menopause problem—hot flashes, night sweats, bleeding concerns, or an HRT decision—and want ongoing women’s midlife care that may include clinically indicated laboratory orders.	Midi is video-only. It is not an RLS specialty service, cannot perform a neurologic exam or sleep study, and does not guarantee that a particular test, prescription, or referral will be issued. Cancel or reschedule at least 24 hours ahead to avoid a cancellation fee, according to Midi’s current published guidance.
Sesame	Cash-pay marketplace that does not bill insurance; clinicians set prices and the amount is shown before booking; virtual providers may issue referrals, lab orders, or paperwork when clinically appropriate; online lab ordering is available only in certain states; virtual appointments generally require cancellation at least 3 hours ahead for a refund, and in-person appointments at least 24 hours ahead. (Virtual care; Terms)	You want to compare available cash-pay primary-care or specialist appointments and can evaluate the individual clinician’s specialty, price, location, and format before paying.	Marketplace availability and RLS expertise vary by clinician and location. A lab order, referral, prescription, neurologic exam, or sleep study is not guaranteed by booking a general virtual visit.

Need ongoing menopause care for the symptoms HRT actually treats?

Midi may fit when hot flashes, night sweats, bleeding changes, or the separate HRT decision need ongoing virtual menopause care—and you understand that RLS may still need primary care, sleep medicine, neurology, or in-person assessment. Check Midi availability, current pricing, and your exact insurance plan → Sponsored link. We may earn a commission if you book. Coverage and patient cost must be confirmed for your exact plan before the visit.

Need a cash-pay appointment you can compare before booking?

Sesame can show currently available virtual or in-person clinicians and provider-set prices. Choose the specialty and appointment that match the question you need answered—not merely the earliest slot. Browse available Sesame appointments → Sponsored link. We may earn a commission if you book. Sesame does not bill insurance, and the clinician—not the marketplace—decides whether labs, referrals, or prescriptions are appropriate.

---

Will restless legs go away after menopause?

The short answer: Nobody can promise that. RLS can improve, worsen, remit for a period, or persist. Correcting a specific contributor—iron status being the clearest example—can improve symptoms, but RLS often behaves as a long-term condition and becomes more common with age rather than disappearing at a guaranteed hormonal endpoint.

We considered giving you a menopause-specific percentage. There is not a good one to give. The prognosis research is too thin to turn “after menopause” into a deadline.

Watch the things that actually change decisions:

• How many nights a week it happens and what time it starts.
• Whether movement still relieves it.
• Whether symptoms spread to the arms or start earlier in the day.
• What happens after a medication change or iron treatment.
• Whether snoring, gasping, or dangerous daytime sleepiness suggests a second sleep problem.
• How much sleep you are losing and whether driving or work is becoming unsafe.

Waiting is the wrong plan when symptoms are getting more frequent or intense, sleep deprivation is severe, daytime sleepiness is unsafe, numbness or weakness persists, symptoms changed after a medicine, or any urgent warning sign is present.

---

What should I bring to an appointment for restless legs?

The short answer: Bring a seven-night record, a complete list of prescriptions, over-the-counter products, and supplements, the actual laboratory reports rather than the word “normal,” and a clear description of what movement does to the sensation. That gives a clinician enough structure to apply the criteria and spot contributors.

Printable restless legs appointment record

Print or save this section before the appointment. Do not fill it from memory in the waiting room.

Seven-night pattern record

Night	Start and stop time	What were you doing when it started?	Where was it, and what did it feel like?	Did movement help? For how long?	Medicines, alcohol, caffeine, bleeding, or unusual sleep that day	Sleep lost / next-day effect
1
2
3
4
5
6
7

Five-criteria check

Criterion	Yes	No	Unsure	What happened in your own words
Urge to move the legs, usually with an uncomfortable sensation
Starts or worsens during rest
Movement relieves it while moving
Worse in the evening or at night
No better explanation fits

Medication and product timeline

Prescription, OTC product, or supplement	Dose / active ingredient	Start or change date	Time taken	When leg symptoms changed	Benefit it gives you

Iron results

Test	Your result	Laboratory reference range	Date and time drawn	Notes
Ferritin
Serum iron
Total iron-binding capacity
Transferrin saturation
Hemoglobin / CBC

RLS discussion points—not self-treatment instructions:

• AASM: consider iron treatment at ferritin ≤75 ng/mL or transferrin saturation <20%; ferritin 75–100 ng/mL is the IV-only consensus band.
• 2026 Mayo algorithm: selected clinically significant cases may enter an IV-iron discussion up to ferritin 300 ng/mL when transferrin saturation is <45% and the rest of the conditions fit.
• Ferritin assay method can materially change the printed number, so transferrin saturation and the full clinical picture matter.

Seven questions to ask

1. Does my description meet all five RLS criteria?
2. If not, which diagnosis fits the parts that do not match?
3. Which iron studies are appropriate, and how will you interpret them specifically for RLS?
4. Could any prescription, OTC product, or supplement be aggravating this?
5. Do my bleeding changes need a separate evaluation?
6. Would sleep medicine or neurology add anything, and what question would a sleep study answer?
7. If medication is considered, how will we monitor side effects and augmentation?

Seven nights of specific observations beat seven months of “It happens all the time.” Hand over the page and spend the visit on the answers instead of the setup.

---

What did we actually verify for this page?

The short answer: We checked the diagnostic criteria, treatment guidance, iron thresholds, FDA indications, menopause evidence, magnesium evidence, emergency warning signs, and every provider fact used in a CTA. We also separated verified facts from editorial routing judgments and left unresolved questions unresolved.

Primary medical and regulatory sources checked in August 2026

• IRLSSG diagnostic criteria: Allen RP, Picchietti DL, Garcia-Borreguero D, et al. Sleep Medicine 2014;15(8):860–873. (PubMed)
• AASM clinical practice guideline: Winkelman JW, Berkowski JA, DelRosso LM, et al. Journal of Clinical Sleep Medicine 2025;21(1):137–152. (PubMed)
• 2026 management algorithm: Silber MH, Berkowski JA, Buchfuhrer MJ, et al., for the Restless Legs Syndrome Foundation scientific and medical advisory board. Published online May 26, 2026. (Publisher)
• IRLSSG iron consensus: Allen RP, Picchietti DL, Auerbach M, et al. Sleep Medicine 2018;41:27–44. (PubMed)
• Ferritin-assay comparison: Silber MH, Block DR, St. Louis EK. Journal of Clinical Sleep Medicine 2025;21(1):65–67. (PubMed)
• Randomized estrogen trial: Polo-Kantola P, Rauhala E, Erkkola R, Irjala K, Polo O. Obstetrics & Gynecology 2001;97(4):548–554. (PubMed)
• Menopause association studies: Wesström et al. 2008 (PubMed) and Wesström et al. 2014 (PubMed)
• One-patient estradiol case report: Hachul et al. 2007. (PubMed)
• Magnesium evidence: Marshall et al. 2019 (PubMed) and Jadidi et al. 2022 (PubMed)
• Menopause nonhormone therapy statement: The Menopause Society, 2023. (PubMed)
• FDA indications and compounded-drug status: current FDA drug labels and FDA menopause and compounding pages.
• Emergency warning signs: CDC blood-clot and stroke guidance.

Provider-stated facts checked August 5, 2026

• Midi Health: availability in all 50 states; self-pay visit prices; PPO language; Medicare, Medicaid, and Medi-Cal restrictions; virtual format; and clinically indicated lab or imaging orders. Prices do not include every possible outside laboratory, imaging, medication, deductible, coinsurance, or copay cost.
• Sesame: cash-pay model; provider-set prices shown before booking; no insurance billing; virtual paperwork, referral, and lab-order language; state limits for online lab ordering; and cancellation windows.

What is verified, what is our judgment, and what is not ours to decide

• Verified fact: the five criteria, current guideline recommendations, stated thresholds, FDA indications, study designs, provider-published prices and policies, and the numbers in the evidence tables.
• Evidence-limited conclusion: menopause may be when RLS becomes noticeable, but a direct falling-estrogen cause is not established.
• Editorial judgment: primary care is the best default starting point for many readers because it can coordinate the symptom history, exam, full iron panel, medication review, bleeding evaluation, and referral.
• Not ours to decide: your diagnosis, the cause of your symptoms, whether you should receive oral or IV iron, which prescription fits, whether HRT is appropriate, or whether a virtual visit can safely replace an in-person exam.

What remains unanswered

• No randomized trial has tested HRT in women selected for diagnosed RLS.
• Current RLS guidance does not establish whether fezolinetant, elinzanetant, or oxybutynin improves or worsens RLS.
• A ferritin result between 100 and 300 does not resolve IV-iron eligibility by itself; current expert documents use different ranges and still require clinical selection.
• No study can tell an individual woman whether symptoms will disappear after menopause.

Why only two provider paths appear here

Our review framework, The HRT Index Verification Standard, evaluates providers on clinical legitimacy, care quality, medication fit, price transparency, and access—in that order.

This page is not a provider ranking. We included only two late-stage routes that can plausibly help with a real next action: ongoing menopause care when menopause symptoms are a separate problem, or a cash-pay appointment marketplace when the reader needs to find available care. We did not route the central RLS question toward questionnaire-only HRT programs, compounded-hormone programs, or any service that would imply hormone therapy treats RLS.

We may earn commissions from the sponsored provider links. That does not change the central finding: HRT is not an established RLS treatment, and an HRT affiliate is not automatically the right first stop.

See our corrections and update log

---

Frequently asked questions about menopause and restless legs syndrome

Is restless legs syndrome a symptom of perimenopause?

Many women first notice RLS during perimenopause, but it is not specific to perimenopause and timing alone does not prove hormones caused it. Apply the five criteria, then check iron status, medicines, sleep apnea, bleeding, and mimics before settling on a hormonal explanation.

Can low estrogen cause restless legs?

A direct low-estrogen cause has not been established. Estrogen and dopamine biology make it a plausible research question, but no study has shown that falling estrogen causes RLS in women, and hormone levels are not part of the diagnostic criteria.

Does HRT help restless legs syndrome?

HRT is not an established or guideline-recommended RLS treatment. The only randomized estrogen trial found no benefit on nighttime periodic limb movements, which are related to but not identical to RLS. HRT may improve hot flashes and night sweats that are separately breaking your sleep.

Can HRT make restless legs worse?

No randomized trial has answered that. If symptoms changed after starting, stopping, or changing HRT, record the exact product, route, dose, and dates and review the timeline with the prescriber rather than stopping on your own.

Can low iron matter even if I am not anemic?

Yes. A normal hemoglobin does not rule out an RLS-relevant ferritin or transferrin-saturation result. That is why current guidance asks for iron studies rather than relying on a CBC alone.

What ferritin level is considered low for restless legs?

The 2025 AASM good-practice statement considers iron treatment at ferritin 75 ng/mL or below or transferrin saturation under 20%. Ferritin 75–100 ng/mL is its IV-only consideration band. The 2026 Mayo algorithm permits a broader selected-patient IV discussion up to ferritin 300 ng/mL when transferrin saturation is below 45% and the rest of the clinical criteria fit.

My ferritin is 40 and my doctor said it was normal. Can it still matter?

It may be inside your laboratory’s printed reference range and still be below the RLS treatment-consideration threshold. Both facts can be true. Ask for interpretation in the context of the full symptom pattern and transferrin saturation rather than treating the number on your own.

Should I take iron for restless legs?

Not before testing and clinician review. Iron can obscure your untreated baseline, cause side effects, and be harmful when iron stores or transferrin saturation are already high. A low result also needs a cause, not merely a supplement.

Is magnesium proven to help restless legs?

No. The 2019 systematic review could not conclude that magnesium was effective, and a later add-on trial does not prove that magnesium works by itself. Do not let it substitute for the RLS criteria, full iron panel, medication review, and sleep evaluation.

Which medicines can make restless legs worse?

Current guidance names antihistaminergic, serotonergic, and dopamine-blocking medicines as aggravator categories. In practice, that can include sedating “PM” antihistamines, many antidepressants, and some anti-nausea medicines. Alcohol, caffeine, and untreated obstructive sleep apnea belong on the same first-step list.

Can the antidepressant I take for hot flashes be contributing?

It is worth asking. SSRIs and SNRIs are recommended nonhormonal options for hot flashes, while serotonergic medicines are an RLS aggravator category. A timing relationship is a reason for a prescriber conversation, not abrupt discontinuation.

Is there one option that can help both hot flashes and restless legs?

Gabapentin is explicitly recommended in both the 2023 Menopause Society statement and the 2025 AASM RLS guideline. Whether it fits you depends on your history, kidney function, other sedating medicines, side-effect priorities, and prescriber judgment.

How do I tell restless legs from a leg cramp?

RLS is an urge to move that builds during rest, improves while you move, and is worse in the evening or at night. A cramp is a sudden painful contraction, usually in one muscle, and the muscle may feel hard. You can have both.

Why is restless legs worse at night?

Evening or nighttime worsening is one of the five diagnostic features and reflects a real circadian pattern in RLS. The biology is more complex than one hormone or one neurotransmitter, so a single confident menopause mechanism would overstate the evidence.

Can restless legs affect the arms?

Yes, especially when RLS is severe, long-standing, or augmented by dopaminergic treatment. Arm symptoms also have other explanations, so mention them rather than assuming they are part of RLS.

Do I need a sleep study?

Usually not for a classic RLS presentation. A sleep study becomes more useful when another disorder—often obstructive sleep apnea or unexplained periodic limb movements—is suspected. Ask what specific question the test is meant to answer.

When are leg symptoms an emergency?

RLS itself is not an emergency. New one-sided swelling, tenderness, warmth, or discoloration needs prompt medical assessment for a possible clot. Chest pain, trouble breathing, fainting, a fast or irregular heartbeat, or coughing blood needs emergency care. Sudden face or arm weakness, speech trouble, vision change, or loss of balance also requires 911.

---

What should I remember about menopause and restless legs syndrome?

• The overlap is real; a direct falling-estrogen cause is not proven. The strongest menopause-specific association is with hot flashes and night sweats.
• HRT is not an established RLS treatment. Treat hot flashes with HRT when HRT fits—not because it has been shown to fix RLS.
• The five-part pattern comes first. The urge, rest trigger, movement relief, nighttime timing, and absence of a better explanation matter more than any one sensation word.
• Ask for a full iron panel. Ferritin and transferrin saturation drive the RLS discussion; a CBC alone does not.
• Current experts disagree at the upper edge. The AASM uses 75–100 ng/mL as its IV-only consensus band, while the 2026 Mayo algorithm permits selected-patient consideration up to 300 ng/mL with transferrin saturation below 45%.
• Check the medicine cabinet. Sedating antihistamines, serotonergic medicines, dopamine-blocking medicines, alcohol, caffeine, and untreated sleep apnea can change the pattern.
• Gabapentinoids moved to the front. Dopamine agonists still have FDA RLS indications, but current guidance conditionally recommends against their standard use because of augmentation.
• Magnesium is not the shortcut. The evidence remains inconclusive, and it should not replace testing or diagnosis.

---

Still not sure which HRT program is right for you? Take our free 90-second matching quiz.

RLS may not be a hormone problem. But if hot flashes, night sweats, bleeding changes, vaginal symptoms, or broken sleep are also part of your life, that separate menopause-care decision is worth resolving properly.

Find My HRT Path →

Answer a few questions about your symptoms, state, insurance, and what you are actually looking for. The tool will match you to provider models that may fit—and flag when online care is not the right starting point.

---

Educational editorial research only—not medical advice, not a diagnosis, and not a substitute for care from a clinician who knows your history. Last verified August 2026.